Equities research analysts at Brinson Patrick assumed coverage on shares of Rexahn Pharmaceuticals (NYSE:RNN) in a research note issued to investors on Monday, Analyst Ratings.Net reports. The firm set an “outperform” rating on the stock. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) shares after opening at $1.10 moved to $1.14 on last trade day and at the end of the day closed at $1.01. Company price to cash ratio as 11.89. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) showed a negative weekly performance of -14.41%.
North American Palladium Ltd. (NYSEMKT:PAL) is pleased to announce that it has closed the second tranche, for gross proceeds of $30 million (the “Second Tranche”), of its previously announced public offering of 7.5% convertible unsecured subordinated debentures and associated warrants (the “Offering”). North American Palladium Ltd (USA) (NYSEMKT:PAL) shares advanced 5.38% in last trading session and ended the day on $0.319. PAL return on equity ratio is recorded as -19.80% and its return on assets is -9.10%. North American Palladium Ltd (USA) (NYSEMKT:PAL) yearly performance is -77.46%.
Galena Biopharma Inc. (NASDAQ:GALE), on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 1193.0% when compared to the same quarter one year ago, falling from -$3.75 million to -$48.50 million. Galena Biopharma Inc. (NASDAQ:GALE) shares moved down -8.74% in last trading session and was closed at $1.88, while trading in range of $1.82 – $2.10. Galena Biopharma Inc. (NASDAQ:GALE) year to date (YTD) performance is -62.10%.
Mast Therapeutics Inc. (NYSEMKT:MSTX) on Mar. 26 reported financial results for the fourth quarter and year ended December 31, 2013. Mast Therapeutics Inc. (NYSEMKT:MSTX) weekly performance is -7.69%. On last trading day company shares ended up $0.600. Mast Therapeutics Inc. (NYSEMKT:MSTX) distance from 50-day simple moving average (SMA50) is -21.90%. Analysts mean target price for the company is $2.00.